Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study

被引:2
作者
Liu, Lei [1 ]
Zhou, Yufu
Deng, Shuwen [1 ]
Yuan, Ting [1 ]
Yang, Saiqi [1 ]
Zhu, Xiaoling [1 ]
Wang, Changfa [2 ]
Wang, Yaqin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Dept Gastroenterol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Gen Surg Dept, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Arterial stiffness; Brachial ankle pulse wave velocity (baPWV); Metabolic dysfunction-associated fatty liver (MAFLD); Diabetes; ASIA-PACIFIC REGION; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
D O I
10.1016/j.numecd.2024.03.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to investigate the correlation and to explore which MAFLD subtypes have the greatest influence on progression of arterial stiffness risk. Methods and results: Using data from a health examination-based cohort, a total of 12,129 participants who underwent two repeated health examinations that included brachial-ankle pulse wave velocity (baPWV) from 2012 to 2020 were enrolled. Participants were separated into non-MAFLD, overweight/obese (OW-MAFLD), lean/normal weight (lean-MAFLD) and diabetes (DM-MAFLD) groups. Among the participants with a median follow-up of 2.17 years, 4511 (37.2%) participants had MAFLD at baseline, among which 3954 (87.7%), 123 (2.7%), and 434 (9.6%) were OW-, lean- and DM-MAFLD, respectively. Analyses using linear regression models confirmed that compared with the non-MAFLD group, the elevated baPWV change rates (cm/s/ year) were 12.87 (8.81-16.94), 25.33 (7.84-42.83) and 38.49 (27.88-49.10) in OW, lean and DM -MAFLD, respectively, while the increased change proportions (%) were 1.53 (1.10-1.95), 3.56 (1.72-5.40) and 3.94 (2.82-5.05), respectively. Similar patterns were observed when these two baPWV parameters were transformed in the form of the greatest increase using Cox proportional hazards model analyses. Furthermore, the risk of arterial stiffness progression across MAFLD subtypes presented a significant, gradient, inverse relationship in the order of DM-, lean-, OW with metabolic abnormalities (MA)-, and OW without MA-MAFLD. Conclusion: MAFLD, especially DM-MAFLD and lean-MAFLD, was significantly associated with arterial stiffness progression, providing evidence that stratification screening and surveillance strategies for CVD risk have important clinical implications. (c) 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1890 / 1900
页数:11
相关论文
共 50 条
[41]   Associations of an overall healthy lifestyle with the risk of metabolic dysfunction-associated fatty liver disease [J].
Yuan, Caimei ;
Zhang, Chengjing ;
Geng, Xin ;
Feng, Chengwu ;
Su, Yang ;
Wu, Yinfan ;
Wang, Ying ;
Chen, Li ;
Ding, Qiurong ;
Voortman, Trudy ;
Wang, Hongyang ;
Zong, Geng .
BMC PUBLIC HEALTH, 2024, 24 (01)
[42]   Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024) [J].
Fan, Jian-Gao ;
Xu, Xiao-Yuan ;
Yang, Rui-Xu ;
Nan, Yue-Min ;
Wei, Lai ;
Jia, Ji-Dong ;
Zhuang, Hui ;
Shi, Jun-Ping ;
Li, Xiao-Ying ;
Sun, Chao ;
Li, Jie ;
Wong, Vincent Wai-Sun ;
Duan, Zhong-Ping .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (11) :955-974
[43]   Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease [J].
Choi, Kyu Yeon ;
Kim, Tae Yeon ;
Chon, Young Eun ;
Kim, Mi Na ;
Lee, Joo Ho ;
Hwang, Seong Gyu ;
Lee, Jiwoo ;
Kwak, Mi Kyung ;
Hong, Eun-Gyoung ;
Choi, Yun Mi ;
Ha, Yeonjung .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (06) :2747-2756
[44]   Metabolic dysfunction-associated steatotic liver disease and the heart [J].
Driessen, Stan ;
Francque, Sven M. ;
Anker, Stefan D. ;
Cabezas, Manuel Castro ;
Grobbee, Diederick E. ;
Tushuizen, Maarten E. ;
Holleboom, Adriaan G. .
HEPATOLOGY, 2025, 82 (02) :487-503
[45]   Remnant cholesterol, a potential risk factor of metabolic dysfunction-associated fatty liver disease [J].
Hao, Xuanyu ;
Li, Dongyang ;
Huang, Xingyong ;
Wang, Tingting ;
Wu, Peng ;
Shen, Lufan ;
Zhang, Kai ;
Sun, Siyu .
NUTRITION & METABOLISM, 2025, 22 (01)
[46]   Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study [J].
Han, Eugene ;
Lee, Byung-Wan ;
Kang, Eun Seok ;
Cha, Bong -Soo ;
Ahn, Sang Hoon ;
Lee, Yong-ho ;
Kim, Seung Up .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 152
[47]   Prevalence of metabolic dysfunction-associated fatty liver disease after pancreatic surgery in a historical Belgian cohort and review of the literature [J].
D'Cruz, V. ;
De Zutter, A. ;
van den Broecke, M. ;
Ribeiro, S. ;
de Carvalho, L. Abreu ;
Smeets, P. ;
Lecluyse, C. ;
Pape, E. ;
Callebout, E. ;
Berrevoet, F. ;
Geboes, K. .
ACTA GASTRO-ENTEROLOGICA BELGICA, 2024, 87 (03) :373-380
[48]   Arterial Stiffness, Biomarkers of Liver Fat, and the Development of Metabolic Dysfunction in Metabolically Healthy Population: A Prospective Study [J].
Lin, Lin ;
Wang, Long ;
Du, Rui ;
Hu, Chunyan ;
Lu, Jieli ;
Wang, Tiange ;
Li, Mian ;
Zhao, Zhiyun ;
Xu, Yu ;
Xu, Min ;
Bi, Yufang ;
Wang, Weiqing ;
Ning, Guang ;
Chen, Yuhong .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
[49]   Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease [J].
Tanaka, Marenao ;
Mori, Kazuma ;
Takahashi, Satoko ;
Higashiura, Yukimura ;
Ohnishi, Hirofumi ;
Hanawa, Nagisa ;
Furuhashi, Masato .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (03) :700-711
[50]   Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions [J].
Beygi, Mohammad ;
Ahi, Salma ;
Zolghadri, Samaneh ;
Stanek, Agata .
NUTRIENTS, 2024, 16 (14)